No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.

L Richeldi, S Fletcher, H Adamali, N Chaudhuri, S Wiebe, S Wind, K Hohl, A Baker, R Schlenker-Herceg, S Stowasser, TM Maher

Research output: Contribution to journalArticlepeer-review


Nintedanib and pirfenidone are approved treatments for idiopathic pulmonary fibrosis (IPF). This open-label, two-group trial investigated the pharmacokinetic drug–drug interaction between these two drugs in patients with IPF.

Subjects not treated with antifibrotics at screening (group 1, n=20) received a single nintedanib dose (150 mg) followed by pirfenidone (titrated to 801 mg thrice daily) for 3 weeks, with a further single nintedanib dose (150 mg) on the last day (day 23). Subjects treated with pirfenidone at screening (group 2, n=17) continued to receive pirfenidone alone (801 mg thrice daily) for 7 days, then co-administered with nintedanib (150 mg twice daily) for a further 7 days, before single doses of both treatments on day 16.

In group 1, adjusted geometric mean (gMean) ratios (with/without pirfenidone) were 88.6% and 80.6% for nintedanib area under the plasma concentration–time curve (AUC) and maximum plasma concentration (Cmax), respectively. In group 2, gMean ratios (with/without nintedanib) were 97.2% and 99.5% for pirfenidone AUC and Cmax, respectively. For all parameters, the 90% confidence intervals included 100%, suggesting similar exposure for administration alone and when co-administered. Both treatments were well tolerated.

These data indicate there is no relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone when co-administered in IPF patients.
Original languageEnglish
JournalThe European respiratory journal
Publication statusPublished - 10 Jan 2019


Dive into the research topics of 'No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.'. Together they form a unique fingerprint.

Cite this